

1 **Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium – a prospective cross-**  
2 **sectional nationwide study of residual samples**

3 Herzog Sereina, PhD <sup>1\*</sup>, De Bie Jessie, PhD <sup>2,3\*</sup>, Abrams Steven, Prof <sup>3,4</sup>, Wouters Ine, PhD <sup>2</sup>, Ekinci  
4 Esra, MSc <sup>2</sup>, Patteet Lisbeth, PhD <sup>5</sup>, Coppens Astrid, MSc <sup>5</sup>, De Spiegeleer Sandy, MSc <sup>6</sup>, Beutels  
5 Philippe, Prof <sup>1</sup>, Van Damme Pierre, Prof <sup>2</sup>, Hens Niel, Prof <sup>1,4</sup>, Theeten Heidi, Prof <sup>2</sup>

6 <sup>1</sup> *Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine*  
7 *& Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610 Wilrijk, Belgium.*

8 <sup>2</sup> *Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of*  
9 *Antwerp, B-2610 Wilrijk, Belgium*

10 <sup>3</sup> *Global Health Institute, Department of Epidemiology and Social Medicine, University of Antwerp, B-*  
11 *2610 Wilrijk, Belgium.*

12 <sup>4</sup> *Data Science Institute, I-BioStat, UHasselt, B-3500 Hasselt, Belgium.*

13 <sup>5</sup> *Algemeen Medisch Laboratorium (AML), Sonic Healthcare, B-2020 Antwerp, Belgium.*

14 <sup>6</sup> *Laboratoire Luc OLIVIER, B-5380 Fernelmont, Belgium.*

15

16 \* Herzog Sereina and De Bie Jessie contributed equally to this paper

17

18 Corresponding author:

19 Sereina Herzog, Centre for Health Economics Research and Modelling of Infectious Diseases  
20 (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp,  
21 Universiteitsplein, 1 B-2610 Wilrijk, Belgium; herzog.sereina@gmail.com

## 22 **Research in context**

### 23 **Evidence before this study**

24 From 11 March to 6 July, updates on the COVID-19 pandemic by the World Health Organisation as  
25 well as bulletins from the Belgian Scientific Institute for Public Health, Sciensano, were consulted  
26 daily. Press releases and research reports from all over the world were monitored. Google, PubMed,  
27 *medrxiv*, *bioRxiv* were consulted for peer-reviewed articles and preprints by searching the terms  
28 “seroprevalence SARS-CoV-2” and “COVID-19”. We identified an increasing number of serosurveys  
29 during the course of this study, the majority of which as yet unpublished in peer-reviewed journals.  
30 Only one nationwide peer-reviewed serosurvey was published on July 6, indicating a seroprevalence  
31 of 5.0% in Spain in the period of 27 April – 11 May 2020 (n=61075). Other peer-reviewed studies  
32 assessed seroprevalences in specific subgroups of the population (cities). More large-scale, nationwide  
33 studies are needed to assess the proportion of the population that has recently been in contact with the  
34 virus, which helps to understand the likelihood of asymptomatic infections or infections with mild  
35 symptoms.

### 36 **Added value of this study**

37 This study presents nationwide seropositivity in the Belgian population using serial serological survey  
38 data from five collection periods (March 30<sup>th</sup> - July 5<sup>th</sup> 2020) allowing to monitor acquisition of  
39 infections over three months time. The study period covers a lock-down mitigating the start of the  
40 epidemic as well as a period of release in a densely populated European country (374 persons/km<sup>2</sup>).  
41 Initial weighted overall seroprevalence was higher than expected from reported cases, and increasing  
42 quickly from 2.9% (95% CI 2.3 to 3.6) to 6.0% (95% CI 5.1 to 7.1) over 3 weeks during lockdown  
43 (from 1<sup>st</sup> to 2<sup>nd</sup> collection). The associated seroincidence was estimated at 3.1% (95% CI 1.9 to 4.3).  
44 The seroprevalence stabilized at 6.9% (95% CI 5.9-8.0) in the third collection period, and  
45 subsequently tended to decline to 5.5% (95% CI 4.7-6.5) and 4.5% (95% CI 3.7-5.4). A decrease is  
46 observed comparing the 3<sup>rd</sup> and 5<sup>th</sup> period with a seroincidence of -2.4% (95% CI -1.0 to -3.7)  
47 suggesting fast waning of IgG antibodies. Also age- and sex-specific analyses were conducted.

#### 48 **Implications of all the available evidence**

49 Seroprevalence studies around the world indicate that up to July 2020 a minor fraction of the  
50 population has been exposed to SARS-CoV-2 (e.g. in Spain 5% in May). As antibody titers after mild  
51 infection seem to wane rapidly, seroprevalence estimates might only indicate exposure in the previous  
52 2-3 months. Nevertheless, periodic monitoring of seroprevalence is valuable to understand age and  
53 location specific rapid rises in the force of infection, to control the epidemic, and to avoid a  
54 deconfinement strategy leading to large future waves. The significance of detecting SARS-CoV-2  
55 humoral immune responses, irrespective of cellular immune responses, is currently unknown.  
56 However, if seropositivity correlates to some extent with immunity the low peak levels of  
57 seropositivity observed during this study and their rapid decline suggest that mass vaccination  
58 programmes are essential to build up sufficient population immunity.

59 **Abstract**

60 **Background** In the first weeks of the COVID-19 epidemic in Belgium, a repetitive national serum  
61 collection was set up to monitor exposure through SARS-CoV-2 antibody detection. Main objectives  
62 were to assess the evolving age-, sex and region specific seroprevalence and seroincidence under the  
63 influence of a national lock-down, which started on 17<sup>th</sup> March.

64 **Methods** This prospective serial cross-sectional nationwide seroprevalence study, stratified by age,  
65 sex and region, contains 3000-4000 samples in each of its five collection periods (March 30<sup>th</sup> – July 5<sup>th</sup>  
66 2020). In residual sera taken outside hospitals and collected by diagnostic laboratories, IgG antibodies  
67 against S1 proteins of SARS-CoV-2 were measured with a semi-quantitative commercial ELISA.  
68 Seropositivity (cumulative, by age category and sex) and seroincidence over 3 to 4 week periods were  
69 estimated for the Belgian population.

70 **Findings** The weighted overall seroprevalence initially increased from 2.9% (95% CI 2.3 to 3.6) to  
71 6.0% (95% CI 5.1 to 7.1), implying a seroincidence of 3.1% (95% CI 1.9 to 4.3) between the 1<sup>st</sup> and  
72 2<sup>nd</sup> collection period. Thereafter, seroprevalence stabilized and decreased from the 3<sup>rd</sup> to 5<sup>th</sup> period  
73 from 6.9% (95% CI 5.9 to 8.0) to 4.5% (95% CI 3.7 to 5.4).

74 **Interpretation** During lockdown, a small but increasing fraction of the Belgian population showed  
75 serologically detectable signs of exposure to SARS-CoV-2. The decrease observed afterwards most  
76 probably reflects rapid waning of IgG antibodies.

77 **Funding** Antwerp University Fund, the Flemish Research Fund, and European Horizon 2020.

## 78 **Introduction**

79 The World Health Organization (WHO) announced on 11 March 2020, that the SARS-CoV2 outbreak  
80 that started in December 2019 became a pandemic.<sup>1</sup> Clinical symptoms caused by the virus include  
81 loss of taste and smell, fever, malaise, dry cough, shortness of breath, and respiratory distress.  
82 Reported illnesses have ranged from very mild to severe (from progressive respiratory failure to  
83 death).<sup>2</sup> In addition, increasing age, male sex, smoking, and comorbidities such as cardiovascular  
84 diseases and diabetes have been identified as risk factors for developing severe illness.<sup>3</sup> By mid July  
85 2020, over 12 million confirmed cases in 216 countries were reported to be infected by SARS-CoV-2  
86 causing coronavirus disease 2019 (COVID-19).<sup>4</sup>

87 Currently, there is no vaccine or effective cure available to protect against or treat COVID-19.  
88 Therefore, unprecedented measures such as physical distancing, large-scale isolation and closure of  
89 borders, schools and workplaces were considered in many countries to mitigate the spread of the  
90 disease and to reduce the corresponding pressure on the respective healthcare systems.

91 In Belgium, the first confirmed case was reported on 4 February 2020, an asymptomatic person  
92 repatriated from Wuhan.<sup>5</sup> The first locally transmitted cases were confirmed on 2 March 2020.  
93 Thereafter, the number of confirmed COVID-19 cases rapidly increased. The Belgian Scientific  
94 Institute for Public Health, Sciensano, reported that as of 9 July 2020, 62210 cases were confirmed  
95 (0.5% of the Belgian population; 6.6% of the tested individuals) and 9778 died. The majority of the  
96 reported Belgian cases are in the age category of 80-89 years (19.0%; 11805/62210).<sup>6</sup> Knowledge on  
97 and quantification of the age-specific susceptibility to SARS-CoV-2, and its evolution over time,  
98 related to control measures that have been taken, is tremendously important to guide policy makers  
99 aiming to control the epidemic wave and potential future waves as a result of an insufficient herd  
100 immunity level in the population. These needs were translated into the following research objectives:  
101 (1) to constitute a national serum bank on a periodic basis (cross-sectional study design) in order to  
102 estimate the seroprevalence and seroincidence in Belgium and to follow-up trends herein over time  
103 and (2) to estimate the age-specific prevalence of SARS-CoV-2 antibodies in order to identify age  
104 groups that have been infected versus those that are still susceptible as a function of time. The current

105 nationwide study presents background seropositivity (overall, by age category, sex) in the Belgian  
106 population using serial serological survey data from five collection periods (March 30<sup>th</sup> – July 5<sup>th</sup>),  
107 which covers: (a) the implementation of the lockdown during the start of the epidemic, (b) the full  
108 lockdown period (13 March – 4 May 2020), and (c) the period when confinement measures eased (4  
109 May onwards).

## 110 **Methods**

### 111 **Study design**

112 This prospective cross-sectional nationwide seroprevalence study is conducted in individuals aged 0-  
113 101 years. In each collection period, sera were collected over one week's time. The five collection  
114 periods represent different exposure periods: (1) 30 March – 5 April 2020, mainly represents exposure  
115 before the lockdown; (2) 20 – 26 April 2020, represents exposure prior to and during the start of the  
116 lockdown; (3) 18 – 25 May 2020, represents exposure in full lockdown; (4) 8 – 13 June 2020,  
117 represents exposure during period of first relaxation of confinement measures (re-opening of shops);  
118 and (5) 29 June – 4 July 2020, represents changes during further relaxations (partial school re-opening,  
119 opening of restaurants). A serum bank covering all Belgian regions was constituted by collecting  
120 residual sera from ten private diagnostic laboratories in Belgium. Large laboratories were engaged,  
121 with high daily throughput covering primary care and all kinds of ambulatory specialist care outside  
122 hospital. To avoid overrepresentation of subjects with acute and/or severe illness, samples collected in  
123 hospitals were excluded. Each laboratory was allocated a fixed number of samples per age group  
124 (defined in 10-year age bands, the oldest age group with  $\geq 90$  years), per region (Wallonia, Flanders,  
125 Brussels), and per collection period. The number of samples was stratified by sex within each age  
126 group.

127 The study protocol was approved by the Ethics Committee of the University Hospital Antwerp-  
128 University of Antwerp on March 30, 2020 (ref 20/13/158; Belgian Number B3002020000047) and  
129 agreed with inclusion without informed consent, on the condition of the samples being collected  
130 unlinked and anonymously (see appendix for study protocol).

### 131 **Sample size**

132 The sample size per periodical collection has been calculated according to: (1) previous experience  
133 with various age-specific analyses of seroprevalence data in Belgium,<sup>7</sup> (2) estimates of the number of  
134 COVID-19 infected people in Belgium and (3) the estimated evolution of the epidemic curve. Based  
135 on case numbers (hospitalized cases confirmed with COVID-19), the overall prevalence of COVID-19

136 infection at the start of the study was estimated to be about 0.4% (42797/11460000). Based on the  
137 hypothesized overall prevalence, a total sample size of 4000 in the first collection round ensures the  
138 estimation of the overall prevalence with a margin of error of 0.2%; the precision regarding the age-  
139 specific prevalence estimates is lower due to the division of samples across the age groups. However,  
140 an increase in prevalence was expected during the study period. In total, up to 16000 sera were  
141 planned to be collected, distributed over five periodic collections, and for each data collection target  
142 numbers per age group were adapted according to feasibility, sample availability and aiming at  
143 maximizing precision and assessing the impact of a change in epidemic control policy. The actual  
144 number of samples collected per period are indicated in the result section. In collection period 1  
145 (n=4000), the planned 400 samples per age category was not reached for the age categories 0-20 and  
146  $\geq 90$ . From collection period 2 onwards (n=3000), efforts were increased to collect samples in the  
147 youngest age categories and target numbers in 70+ were decreased to maximize overall precision.

#### 148 **Sample preparation and analysis**

149 After centrifugation of blood samples, selected residual sera (minimum 0.5 mL) were kept in the  
150 fridge (4-8°C) for a maximum of 14 days and finally stored at -20°C. Serology results were obtained  
151 through a semi-quantitative test kit (EuroImmun, Luebeck, Germany), measuring IgG antibodies  
152 against S1 proteins of SARS-CoV-2 in serum (ELISA). The test was performed as previously  
153 described by Lassaunière *et al.*<sup>8</sup> The Dutch Taskforce Serology has compared all available data using  
154 the EuroImmun ELISA and determined a specificity of 99.2% and sensitivity ranging from 64.5% to  
155 87.8% in pauci-symptomatic patients and patients with severe disease, respectively, using samples  
156 from patients >14 days after onset of disease symptoms.<sup>9</sup> Presence of detectable IgG antibodies  
157 indicates prior exposure to SARS-CoV-2, an infection which may be resolved or is still resolving, and  
158 possibly protection against reinfection.<sup>8,10</sup>

#### 159 **Data management**

160 Data collected for each sample include: unique sample code, sample date, age (in years), sex, and  
161 postal code of the place of residence. From the second collection period onwards, for each sample it



162 was recorded whether or not a COVID-19 diagnostic (PCR) test was requested at the collecting  
163 laboratories. Samples were delivered anonymously to the investigators. Triage and check for  
164 duplicates was done in the collecting laboratories before anonymization.

165 Each collection period, data were checked for completeness (based on age, sex, and postal code).  
166 Serological results (SARS-CoV-2 antibodies) were linked to the database based on the sample code.  
167 No further data entry was required. All files were kept on a secured server at the University of  
168 Antwerp, with restricted access. Data will be stored for 20 years.

### 169 **Statistical analysis**

170 The serostatus of an individual was considered to be positive if the measured IgG OD values were  
171  $\geq 1.1$ , equivocal IgG values were considered negative. Descriptive analysis included mapping of  
172 sample origin as well as serostatus (crude figures) up to municipality level per collection period.

173 For all analyses, the overall seroprevalence estimate and estimates by 10-year age bands, and sex for  
174 each collection period were derived by fitting generalized linear models (binomial outcome  
175 distribution) to the serostatus of the weighted samples for each collection period. Weighted  
176 seroprevalence estimates are stated with the asymptotic 95% CIs using the design-based standard  
177 errors. The overall seroincidence estimate and estimates by 10-year age bands, and sex between  
178 collection periods were derived by calculating the difference between the corresponding estimated  
179 seroprevalence from generalized linear models (binomial outcome distribution) fitted to the serostatus  
180 of the weighted samples including an interaction term for the collection period. Weighted  
181 seroincidence estimates are displayed with corresponding 95% CIs constructed using the multivariate  
182 delta method to quantify the variability thereabout.<sup>11</sup>

183 We assigned for each collection period weights to the samples such that they replicate the Belgian  
184 population structure according to age, sex and provinces for 2020.<sup>12</sup> Weights are computed by  
185 comparing the sample and population frequencies, i.e. we used a complete cross frequency table for  
186 sex and 10-year age bands and a marginal distribution for the provinces. Weights were trimmed to a

187 maximum value of 3 to reduce the influence of samples in under-represented strata. All analyses were  
188 done with the statistical software R (version 4.0.2) using the package survey (version 4.0).<sup>13</sup>

189 **Role of the funding source**

190 The funders had no role in study design, data collection, data analysis, data interpretation, writing or  
191 submitting of the report. The corresponding author had full access to all the data in the study and had  
192 final responsibility for the decision to submit for publication.

## 193 **Results**

194 A total of 16532 serum samples were collected over five 1 week periods in –March 30<sup>th</sup>-July 5<sup>th</sup> to  
195 measure the anti-SARS-Cov2 IgG sero-status. The regional, age, and sex distribution of these samples  
196 are shown in Table 1; deviations from the population distribution were taken into account in the  
197 estimation of the weighted seroprevalences. Figure 1 shows exemplary for the collection periods 1, 2,  
198 and 5 that the origin of the samples was nicely distributed throughout Belgium (panel A-C) and that  
199 positive samples were spread over municipalities across Belgium (panel D-F); Figure S1 (appendix)  
200 shows all collection periods. The proportion of samples that had been taken to diagnose SARS-COV2  
201 infection was 2-3% in 1<sup>st</sup> and 2<sup>nd</sup> collection and afterwards 10-11%.

202 At the start, the seroprevalence estimates per age category ranged between 1.4% (20-30 years) and  
203 5.9% (0-10 years) in collection period 1. The weighted overall seroprevalence showed a significant  
204 increase between collection period 1 and 2, i.e. from 2.9% (95% CI 2.3 to 3.6) to 6.0% (95% CI 5.1 to  
205 7.1) over a period of 3 weeks (Figure 2, panel A) which is also shown by the overall seroincidence  
206 estimate of 3.1% (95% CI 1.9 to 4.3) (Figure 2, panel D). This significant increase in seroprevalence is  
207 reflected in the age categories 20-30, 80-90, and  $\geq 90$  as indicated by the seroincidence estimates  
208 (Figure 2, panel B+E) and within each sex (Figure 2, panel C+F). Among age categories in collection  
209 period 2, the seroprevalence of the oldest category ( $\geq 90$  years) significantly differed from the  
210 seroprevalences in age categories 10-20, 30-40, 60-70, and 70-80 years.

211 In comparison with period 2, the overall seroprevalence stabilized thereafter to 6.9% (95% CI 5.9-8.0),  
212 5.5% (95% CI 4.7-6.5) and 4.5 (95% CI 3.7-5.4) as shown in Figure 2 (panel A), however, a  
213 significant decrease is observed when comparing the 3<sup>rd</sup> and 5<sup>th</sup> period with a seroincidence of -2.4%  
214 (95% CI -1.0 to -3.7). This decrease was also observed for two subgroups: age category 40-50, and  
215 females. No significant differences between males and females in seroincidence or in seroprevalence  
216 were identified in any of the periods.

## 217 **Discussion**

218 This study reports seroprevalence and seroincidence estimates of IgG antibodies against S1 proteins of  
219 SARS-CoV-2 in Belgium based on 16532 residual sera periodically collected from 30 March – 4 July  
220 2020. The results indicate the state of the COVID-19 epidemic in Belgium, showing that only 2.9%  
221 (95% CI 2.3-3.6) of the Belgian population had detectable antibodies against SARS-CoV-2 at the start  
222 of lockdown, which doubled to 6.0% (95% CI 5.1-7.1) three weeks later but stabilized thereafter to  
223 6.9% (95% CI 5.9-8.0), 5.5% (95% CI 4.7-6.5) and even decreased to 4.5% (95% CI 3.7-5.4).  
224 Seropositive cases were spread over the country from the beginning. These results indicate that  
225 although Belgium was heavily affected by the COVID-19 pandemic<sup>14</sup>, at the end of the study period  
226 only about 7 in hundred people had (recently) been in contact with the virus.

227 Because little is known about the medical history of subjects of whom residual samples are collected,  
228 any potential bias is difficult to identify and control for when estimating seroprevalences. In this study,  
229 the potential for selection bias was reduced by enrolling multiple large laboratories in Belgium that  
230 collect samples from ambulatory patients throughout Belgium visiting their doctor (mainly general  
231 practitioners) for any reason including check-up, follow-up of pathology, allergy. Samples originating  
232 from hospitals were excluded from the study to avoid disproportionate selection of subjects with acute  
233 and/or severe illness including COVID-19. The majority of analyzed samples originated from two  
234 private routine laboratories in Flanders (AML) and Wallonia (laboratoire Luc OLIVIER), each with a  
235 large geographical network. These laboratories received 8000-23000 samples weekly for a variety of  
236 purposes (biochemistry, immunochemistry, hematology, etc.). For example, among the randomly  
237 selected female samples in fertile age (15-45), 11.8% had been taken for pregnancy testing, which  
238 does not suggest overselection of pregnant females. From the total of 11000-33000 samples that were  
239 weekly received by both labs, a fraction (1/3 to 1/11) samples were randomly selected according to the  
240 stratification by age category and provinces and analyzed in this study. Residual sera have previously  
241 been used in serosurveillance studies in numerous countries, including Belgium<sup>7</sup>, and can provide  
242 valuable and representative information on immunity against infectious diseases for the general  
243 population.<sup>15</sup>

244 Stringent containment measures were enforced in Belgium as of 13 March 2020. These included travel  
245 bans, closures of schools, shops, factories and social gatherings in an effort to contain the spread of  
246 COVID-19 and decrease its burden on public health. These intervention measures slowed down the  
247 number of COVID-19 patients that were hospitalized daily. In the first two weeks of the lockdown (up  
248 to 25 March 2020), over 500 cases were hospitalized daily, and this growth rate halved 4 weeks later.<sup>6</sup>  
249 By 26 April 2020, 0.1% of the Belgian population had been hospitalized for COVID-19  
250 (14639/11.46x10<sup>6</sup>) and 0.4% of the Belgian population had tested positive for SARS-CoV-2  
251 (46134/11.46x10<sup>6</sup>) on a total of 345047 screened patients.<sup>6</sup> The estimated seroprevalence in the week  
252 of 20-26 April 2020 (6.0%, 95% CI 5.1 to 7.1) indicates that far more people had generated antibodies  
253 against SARS-CoV-2 and thus had been in contact with the virus than what was expected from the  
254 number of COVID-19 confirmed cases reported in Belgium on 26 April 2020 (0.4%). Clearly, the  
255 reported numbers of COVID-19 confirmed cases represent an underestimation and were influenced by  
256 the testing policy as testing was initially focused on the most severe cases, presenting to hospitals.  
257 Asymptomatic and mild cases were less likely reported and at different stages of the first epidemic  
258 wave, varying proportions of symptomatic cases presented to primary care, and varying proportions of  
259 these cases were tested. By end of June, the number of daily hospital admissions in Belgium dropped  
260 below 20 and the number of confirmed COVID-19 cases stabilized at a lower level than the estimated  
261 seroprevalence in Belgium (see Table 2). The current seroprevalence study in the general population  
262 thus allows in combination with the reported confirmed COVID-19 cases, to estimate the total number  
263 of recently acquired SARS-CoV-2 infections in Belgium.

264 From the above it is clear that determination of the extent of spread of SARS-CoV-2 is a challenge as  
265 typically symptomatic patients are more likely to be diagnosed. In contrast, mainly asymptomatic and  
266 pauci-symptomatic subjects were included in the current study suggesting an **underestimation** of the  
267 cumulative incidence of SARS-CoV-2 infection in the population. Moreover, the sensitivity of the  
268 serological test used depends on the time since the onset of symptoms,<sup>8</sup> thereby preventing a fraction  
269 of the infected subjects to test seropositive if not infected long enough or too long prior to testing. By  
270 day 14 after symptom onset, IgG against SARS-CoV-2 are detectable in serum of the majority of

271 patients.<sup>2</sup> Possibly, recent SARS-CoV-2 infected subjects may have been included in the current  
272 seroprevalence study of whom antibodies were not yet detectable in blood. SARS-CoV-2 infected  
273 subjects with mild or no symptoms of whom it is reported that they may develop low or no antibodies  
274 against SARS-CoV-2, may have been included in this study as well.<sup>16</sup> Moreover, recently it has been  
275 reported that IgG levels start to decrease within 2-3 months after infection with SARS-CoV-2<sup>17-19</sup>,  
276 potentially explaining the observed decline in the 5<sup>th</sup> collection round. As a result, both pauci-  
277 symptomatic subjects as well as subjects that suffered from a SARS-CoV-2 infection more than 2-3  
278 months ago may have been falsely seronegative, and thus also cause underestimation of the incidence  
279 of infection.

280 Male **sex** has been identified as a risk factor for severe COVID-19 disease. However, SARS-CoV-2  
281 susceptibility is similar for males and females and thus no difference in seroprevalence is to be  
282 expected based on sex.<sup>20</sup> Nevertheless, one could argue that symptomatology goes hand-in-hand with  
283 the initiation and extent of a humoral response. Since probably no severe symptomatic cases were  
284 included in this study, any effect of disease severity and concomitant extent in humoral response in  
285 males is not detectable.

286 The uneven infection rate of SARS-CoV-2 hampers the comparison of seroprevalence between  
287 countries. A meta-analysis by Levesque et al.<sup>21</sup> reported a seroprevalence of 14% in Gangelt  
288 (Germany, 30 March – 10 April 2020, lockdown by 22 March, 100 households). A Swiss study  
289 (Geneva, 6 April – 9 May 2020, physical distancing measures by 20 March, 1339 households)  
290 estimated an increasing seroprevalence, from 4.8% (95% CI 2.4-8.0, n=341) to 8.5% (5.9-11.4,  
291 n=469), to 10.9% (7.9-14.4, n=577), to 6.6% (4.3-9.4, n=604), and 10.8% (8.2-13.9, n=775) in five  
292 subsequent weeks.<sup>22</sup> A weekly serological study in Sweden (country in ‘low-scale’ lockdown) showed  
293 a seroprevalence of 7.3% (n=1104) in Stockholm in the week of 27 April 2020.<sup>23</sup> In Spain (start  
294 lockdown 14 March 2020), a national seroprevalence of 5% (4.7-5.4, n=61075) was reported in the  
295 period from 27 April – 11 May 2020.<sup>24</sup> Other preliminary serological surveys from EU Member States  
296 and USA reported that 1.0 - 3.4% of asymptomatic adult blood donors had antibodies against SARS-  
297 CoV-2 virus in the period 20 March – 12 April 2020 (i.e. first month in lockdown in reported

298 countries).<sup>25</sup> In London (UK, start lockdown 23 March 2020), adjusted seroprevalence estimates  
299 increased from 1.5% (end of March), to 15.4% (18 – 24 May 2020) and remained stable at 14.9% (8 –  
300 14 June 2020). In the rest of the UK, seroprevalences are more consistent with other reports, indicating  
301 between 6.3% and 6.9% (8 – 14 June 2020).<sup>26</sup> These seroprevalence estimates, as well as the ones  
302 obtained in the current study provide a consistent picture and increasing incidence of infections across  
303 Europe in spring 2020.

304 The plateauing of seroprevalences in this study is in accordance with findings from the UK<sup>26</sup> and  
305 Spain<sup>24</sup>, and can be attributed to the waning of IgG antibodies against SARS-CoV-2<sup>17-19</sup> in the absence  
306 of large new exposure since the start of the epidemic in Belgium. It implies that seroprevalence studies  
307 on SARS-CoV-2 would only be able to give information on the past 2-3 months. To which extent  
308 these recovered seronegative subjects are prone to reinfection is not known yet, as it depends, among  
309 others, on eventual T-cell dependent immunity induced by the virus.<sup>27</sup> On the other hand, if presence  
310 of the antibodies we measured would correlate to some extent with immunity, levels of seropositivity  
311 observed during this study and their rapid decline suggest that we are still far away from natural herd  
312 immunity. Based on the estimated basic reproduction number ( $R_0$  ranges from 1.4 to 3.9),<sup>28</sup> 50 – 75 %  
313 of a population would need to have protective immunity (humoral or cellular) in order to achieve herd  
314 immunity mitigating subsequent waves of COVID-19.<sup>29</sup> Currently, it seems likely that natural  
315 exposure during this pandemic might not soon deliver the required level of herd immunity and there  
316 will be a substantial need for mass vaccination programmes to save time and lives.<sup>30</sup>

## 317 **Conclusion**

318 Serial seroprevalence monitoring indicates that in Belgium, a densely populated country in the center  
319 of Western Europe, SARS-COV-2 virus was introduced all over the country from start and the  
320 proportion of the population infected doubled within 3 weeks' time from 3% to 6% during the start of  
321 a lockdown to mitigate the epidemic. In line with reported confirmed cases and COVID19 deaths,  
322 seroprevalence plateaued and seroincidence decreased thereafter. However, by the end of the 3-month  
323 study period a decay of the proportion seropositives was observed corroborating recent reports of  
324 quick antibody waning after mild or asymptomatic infection.<sup>17-19</sup> Serial seroprevalence monitoring is a

325 useful tool to estimate the proportion of the population recently infected with the SARS-CoV-2 virus,  
326 and helps to understand the extend of pauci- or asymptomatic infections. The findings were extremely  
327 valuable to calibrate the Belgian response to the epidemic's first wave and to guide policy makers to  
328 control the potential future waves. The latter is still a challenge as the low reported seroprevalences  
329 (2.9-6.9%) are far from required herd immunity levels. Moreover, more research is needed to confirm  
330 if seropositivity correlates to protective immunity against the virus.

### 331 **Data sharing**

332 The authors are willing to share original data on request.

### 333 **Contributors**

334 SH, JDB and IW interpreted study results and drafted and revised the manuscript. SH also contributed  
335 to the study design and planned and performed statistical analysis. SA contributed to the study design,  
336 planned statistical analysis, interpreted study results and revised the manuscript. EE contributed to  
337 drafting the manuscript. LP and AC contributed to the study design, sample analysis and interpreted  
338 the study results and revised the manuscript. SDS contributed to sample analysis and revised the  
339 manuscript. PB, PVD, NH and HT contributed to the study design, interpreted the study results and  
340 revised the manuscript. PVD and HT also conceived the study. NH also planned the conduct of  
341 statistical analysis. All authors had access to all of the data and take full responsibility for the integrity  
342 of the data, the accuracy of the data analysis, and the finished article. The corresponding author attests  
343 that all listed authors meet authorship criteria and that no others meeting the criteria have been  
344 omitted.

### 345 **Declaration of interest**

346 All authors have completed the Unified Competing Interest form available at  
347 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: support to the university from research grants from  
348 GSK Biologicals, Pfizer, SANOFI, Merck, Themis, Osivax, J&J and Abbott and grants from The Bill  
349 & Melinda Gates Foundation, PATH, Flemish Government and European Union, outside the  
350 submitted work; no financial relationships with any organizations that might have an interest in the



351 submitted work in the previous three years; no other relationships or activities that could appear to  
352 have influenced the submitted work.

### 353 **Acknowledgments**

354 This work received funding from the European Union's Horizon 2020 research and innovation  
355 program - project EpiPose (No 101003688), the European Research Council (ERC) under the  
356 European Union's Horizon 2020 research and innovation program (grant agreement 682540  
357 TransMID), the Flemish Research Fund (FWO 1150017N) and from The Antwerp University Fund;  
358 which is a community of donors who contribute to research and education with their personal  
359 commitment through a donation, gift, bequest or through academic chairs.

360 We acknowledge the Belgian laboratories that voluntarily collected sera and data for this study:  
361 Algemeen Medisch Laboratorium (AML, Antwerpen), Laboratoire Luc OLIVIER (Fernelmont),  
362 Declerck Klinisch Laboratorium (Ardoonie), Klinisch Labo RIGO (Genk), Labo Anacura/Nuytinck  
363 (Evergem), Labo Somedi (Heist-op-den-Berg), Labo LBS (Brussels), Laboratoire Bauduin (Enghien),  
364 Medisch labo Bruyland (Kortrijk), Synlab (Luik).

365 **Figure captions**

366 **Figure 1.** Map of Belgium at municipality level, collection period 1, 2, and 5; panel A-C: number of  
367 samples tested in each municipality, panel D-F: presence of IgG-positive (red) versus exclusively IgG-  
368 negative (green) samples in each municipality.

369 **Figure 2.** Weighted seroprevalence (A, B, C) and seroincidence (D, E, F) estimates in Belgium overall  
370 (panel A+D), by 10-year age bands (panel B+E), by sex (panel C+F).

371 **References**

- 372 1 WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 51. [www.who.int/docs/default-](http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf)  
373 [source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf](http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf).
- 374 2 Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of  
375 probable bat origin. *Nature* 2020; **579**: 270–73. <https://doi.org/10.1038/s41586-020-2012-7>.
- 376 3 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with  
377 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054–62.  
378 [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
- 379 4 WHO. Coronavirus disease (COVID-19) outbreak situation.  
380 [www.who.int/emergencies/diseases/novel-coronavirus-2019](http://www.who.int/emergencies/diseases/novel-coronavirus-2019) (accessed Jul 13, 2020).
- 381 5 FOD. Eén gerepatrieerde landgenoot testte positief op het nieuwe coronavirus. [www.info-](http://www.info-coronavirus.be/nl/news/gerepatrieerde-landgenoot-testte-positief-op-het-nieuwe-coronavirus)  
382 [coronavirus.be/nl/news/gerepatrieerde-landgenoot-testte-positief-op-het-nieuwe-coronavirus](http://www.info-coronavirus.be/nl/news/gerepatrieerde-landgenoot-testte-positief-op-het-nieuwe-coronavirus)  
383 (accessed Apr 23, 2020).
- 384 6 Sciensano. Epidemiologische situatie. [https://covid-19.sciensano.be/nl/covid-19-](https://covid-19.sciensano.be/nl/covid-19-epidemiologische-situatie)  
385 [epidemiologische-situatie](https://covid-19.sciensano.be/nl/covid-19-epidemiologische-situatie).
- 386 7 Theeten H, Hutse V, Hoppenbrouwers K, Beutels P, van Damme P. Universal hepatitis B  
387 vaccination in Belgium: impact on serological markers 3 and 7 years after implementation.  
388 *Epidemiol Infect* 2014; **142**: 251–61. <https://doi.org/10.1017/S0950268813001064>.
- 389 8 Lassaunière R, Frische A, Harboe ZB, et al. Evaluation of nine commercial SARS-CoV-2  
390 immunoassays. *medRxiv* 2020. <https://doi.org/10.1101/2020.04.09.20056325>.
- 391 9 Taskforce serologie LCT. Rapportage Status validatie van ELISA en auto-analyzer antilichaam  
392 testen voor diagnostiek van SARS-CoV-2; overwegingen voor gebruik. (versie 19.05.2020).  
393 [www.nvmm.nl/media/3519/20200519\\_status-en-resultaten-validatie-elisa-en-auto-](http://www.nvmm.nl/media/3519/20200519_status-en-resultaten-validatie-elisa-en-auto-analyzers_versie19052020_final.pdf)  
394 [analyzers\\_versie19052020\\_final.pdf](http://www.nvmm.nl/media/3519/20200519_status-en-resultaten-validatie-elisa-en-auto-analyzers_versie19052020_final.pdf).
- 395 10 EUROIMMUN A. Application of EUROIMMUN tests for COVID-19 diagnostics. [www.coronavirus-](http://www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/YI_2606_I_UK_B.pdf)  
396 [diagnostics.com/documents/Indications/Infections/Coronavirus/YI\\_2606\\_I\\_UK\\_B.pdf](http://www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/YI_2606_I_UK_B.pdf) (accessed  
397 Apr 29, 2020).
- 398 11 Cox C. Delta Method. In: Armitage P, Colton T, eds. *Encyclopedia of Biostatistics*. Chichester, UK:  
399 John Wiley & Sons, Ltd, 2005.
- 400 12 Federal Planning Bureau. Population par province et âge, au 1er janvier. [www.plan.be](http://www.plan.be) (accessed  
401 Apr 22, 2020).
- 402 13 Lumley T. survey: analysis of complex survey samples. R package version 4.0.
- 403 14 WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 80. [www.who.int/docs/default-](http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200409-sitrep-80-covid-19.pdf?sfvrsn=1b685d64_6)  
404 [source/coronaviruse/situation-reports/20200409-sitrep-80-covid-19.pdf?sfvrsn=1b685d64\\_6](http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200409-sitrep-80-covid-19.pdf?sfvrsn=1b685d64_6).
- 405 15 Gidding H. Australia's national serosurveillance program. *NSW Public Health Bull* 2003; **14**: 90.  
406 <https://doi.org/10.1071/NB03027>.
- 407 16 van der Heide V. Neutralizing antibody response in mild COVID-19. *Nat Rev Immunol* 2020; **20**:  
408 352. <https://doi.org/10.1038/s41577-020-0325-2>.
- 409 17 Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-  
410 CoV-2 infections. *Nat Med* 2020. <https://doi.org/10.1038/s41591-020-0965-6>.
- 411 18 Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses in  
412 SARS-CoV-2 infection. *medRxiv* 2020. <https://doi.org/10.1101/2020.07.09.20148429>.
- 413 19 Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in  
414 Persons with Mild Covid-19. *N Engl J Med* 2020. <https://doi.org/10.1056/NEJMc2025179>.
- 415 20 Jin J-M, Bai P, He W, et al. Gender Differences in Patients With COVID-19: Focus on Severity and  
416 Mortality. *Front Public Health* 2020; **8**. <https://doi.org/10.3389/fpubh.2020.00152>.
- 417 21 Levesque J, Maybury DW. A note on COVID-19 seroprevalence studies: a meta-analysis using  
418 hierarchical modelling. *medRxiv* 2020. <https://doi.org/10.1101/2020.05.03.20089201>.

- 419 22 Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in  
420 Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet* 2020.  
421 [https://doi.org/10.1016/S0140-6736\(20\)31304-0](https://doi.org/10.1016/S0140-6736(20)31304-0).
- 422 23 Folkhälsomyndigheten. Första resultaten från pågående undersökning av antikroppar för covid-  
423 19-virus. [www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-](http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19-virus)  
424 [resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19-virus](http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19-virus) (accessed May 20,  
425 2020).
- 426 24 Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-  
427 COVID): a nationwide, population-based seroepidemiological study. *The Lancet* 2020.  
428 [https://doi.org/10.1016/S0140-6736\(20\)31483-5](https://doi.org/10.1016/S0140-6736(20)31483-5).
- 429 25 ECDC. Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK - ninth update.  
430 [www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-](http://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-disease-2019-ninth-update-23-april-2020.pdf)  
431 [disease-2019-ninth-update-23-april-2020.pdf](http://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-disease-2019-ninth-update-23-april-2020.pdf) (accessed Apr 23, 2020).
- 432 26 Public Health England. Weekly Coronavirus Disease 2019 (COVID-19) Surveillance Report.  
433 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/897481/Weekly_COVID19_Surveillance_Report_w26_UPDATED.pdf)  
434 [/file/897481/Weekly\\_COVID19\\_Surveillance\\_Report\\_w26\\_UPDATED.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/897481/Weekly_COVID19_Surveillance_Report_w26_UPDATED.pdf).
- 435 27 Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in  
436 protection. *Sci Immunol* 2020; **5**. <https://doi.org/10.1126/sciimmunol.abd6160>.
- 437 28 D'Arienzo M, Coniglio A. Assessment of the SARS-CoV-2 basic reproduction number, R0, based on  
438 the early phase of COVID-19 outbreak in Italy. *Biosafety and Health* 2020; **2**: 57–59.  
439 <https://doi.org/10.1016/j.bsheal.2020.03.004>.
- 440 29 Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher  
441 compared to SARS coronavirus. *J Travel Med* 2020; **27**. <https://doi.org/10.1093/jtm/taaa021>.
- 442 30 Altmann DM, Douek DC, Boyton RJ. What policy makers need to know about COVID-19 protective  
443 immunity. *Lancet* 2020; **395**: 1527–29. [https://doi.org/10.1016/S0140-6736\(20\)30985-5](https://doi.org/10.1016/S0140-6736(20)30985-5).  
444

**Table 1.** Description of the study population, collection period 1 till 5


		Collection period 1		Collection period 2		Collection period 3		Collection period 4		Collection period 5	
		30 Mar – 5 Apr 2020		20 – 26 Apr 2020		18 – 25 May 2020		8 – 13 June 2020		29 June – 4 July 2020	
		n	%	n	%	n	%	n	%	n	%
<b>Number of samples</b>		3910		3397		3242		2960		3023	
<b>Region</b>	<b>Wallonia</b>	1511	38.6	1539	45.3	1292	39.9	1100	37.2	1068	35.3
	<b>Flanders</b>	2195	56.1	1556	45.8	1542	47.6	1526	51.6	1621	53.6
	<b>Brussels</b>	204	5.2	302	8.9	408	12.6	334	11.3	334	11.0
<b>Age in years</b>	<b>0-10</b>	36	0.9	85	2.5	174	5.4	124	4.2	110	3.6
	<b>10-20</b>	294	7.5	442	13.0	431	13.3	375	12.7	413	13.7
	<b>20-30</b>	436	11.2	375	11.0	414	12.8	383	12.9	394	13.0
	<b>30-40</b>	461	11.8	407	12.0	424	13.1	395	13.3	396	13.1
	<b>40-50</b>	468	12.0	406	12.0	411	12.7	394	13.3	403	13.3
	<b>50-60</b>	498	12.7	430	12.7	419	12.9	393	13.3	400	13.2
	<b>60-70</b>	507	13.0	426	12.5	417	12.9	399	13.5	403	13.3
	<b>70-80</b>	506	12.9	316	9.3	236	7.3	201	6.8	204	6.7
	<b>80-90</b>	493	12.6	315	9.3	163	5.0	166	5.6	160	5.3
	<b>≥90</b>	211	5.4	195	5.7	153	4.7	130	4.4	140	4.6
<b>Sex</b>	<b>male</b>	1799	46.0	1599	47.1	1587	49.0	1425	48.1	1471	48.7
	<b>female</b>	2111	54.0	1798	52.9	1655	52.0	1535	51.9	1552	51.3



A


Collection period 1

medRxiv preprint doi: <https://doi.org/10.1101/2020.06.08.20125179>; this version posted July 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).




B

Collection period 2




C

Collection period 5




D

Collection period 1




E

Collection period 2









F

Collection period 5







**Table 2.** Number of confirmed COVID-19 cases versus weighted seroprevalence in Belgium during the different collection periods

	<b>Collection period</b>	<b>Average daily hospitalized cases*</b>	<b>Confirmed COVID-19 cases*</b>	<b>Weighted seroprevalence (with 95% CI)</b>	<b>Weighted seroincidence# (with 95% CI)</b>
<b>1</b>	30 Mar – 5 Apr 2020	499	19691/11.46 milj = 0.2%	2.9% (2.3 to 3.4)	-
<b>2</b>	20 – 26 Apr 2020	204	46134/11.46 milj = 0.4%	6.0% (5.1 to 7.1)	3.1% (1.9 to 4.3)
<b>3</b>	18 – 25 May 2020	27	57342/11.46 milj = 0.5%	6.9% (5.9 to 8.0)	0.9% (-0.6 to 2.3)
<b>4</b>	8 – 13 Jun 2020	23	59918/11.46 milj = 0.5%	5.5% (4.7 to 6.5)	-1.4% (-2.8 to 0.03)
<b>5</b>	29 Jun – 3 Jul 2020	13	61727/11.46 milj = 0.5%	4.5% (3.7 to 5.4)	-1.0 (-2.3 to 0.3)

\*reported at last day of collection period by Sciensano<sup>6</sup>; #; in comparison with previous collection period